Aurora kinase A inhibitor protein kinase inhibitor oncolytic

S. Zhang, Sherif Farag

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

ENMD-2076 is a novel, orally active molecule that has been shown to have significant activity against Aurora kinases and multiple tyrosine-protein kinases, including tyrosine-protein kinase receptor FLT3, protooncogene c-Kit, vascular endothelial growth factor receptor VECFR-2, basic fibroblast growth factor FGFR-1 and FGFR-3, and tyrosine-protein kinase JAK2. ENMD-2076 has potent activity against various cultured tumor cells through multiple effects, including induction of early caspase-dependent apoptosis, modulation of the expression of anti-and proapoptotic proteins to favor cell death, inhibition of the phosphatidylinositol 3-kinase (PI3K)/protein kinase Akt pathway and Aurora kinase A and B, signaling through FGFR-3 and VEGFR, and induction of G 2/M cell cycle arrest. Potent antitumor activity in mice bearing cancer cell lines or human tumor xenografts, including human colorectal cancer, multiple myeloma, leukemia and breast cancer, is also observed. Phase I trials of ENMD-2076 are currently ongoing in solid tumors and hematologic malignancies, with preliminary results showing that the drug has acceptable toxicity and shows promising activity in at least ovarian and colon cancer, multiple myeloma and acute myeloid leukemia. Studies directed at better defining the spectrum of antitumor activity of ENMD-2076 and the relative importance of its apparently different mechanisms of action will allow the design of rational combinations of ENMD-2076 with other anticancer drugs in future clinical trials.

Original languageEnglish (US)
Pages (from-to)5-15
Number of pages11
JournalDrugs of the Future
Volume36
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Aurora Kinase A
Protein Kinase Inhibitors
Multiple Myeloma
Protein-Tyrosine Kinases
Aurora Kinase B
Aurora Kinases
Vascular Endothelial Growth Factor Receptor-3
Phosphatidylinositol 3-Kinase
Cultured Tumor Cells
Fibroblast Growth Factor 1
Vascular Endothelial Growth Factor Receptor-2
Neoplasms
Receptor Protein-Tyrosine Kinases
Fibroblast Growth Factor 2
Hematologic Neoplasms
Caspases
Cell Cycle Checkpoints
Heterografts
Acute Myeloid Leukemia
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Aurora kinase A inhibitor protein kinase inhibitor oncolytic. / Zhang, S.; Farag, Sherif.

In: Drugs of the Future, Vol. 36, No. 1, 2011, p. 5-15.

Research output: Contribution to journalArticle

@article{df1b5b3a7ced4436a4870d7076311c8e,
title = "Aurora kinase A inhibitor protein kinase inhibitor oncolytic",
abstract = "ENMD-2076 is a novel, orally active molecule that has been shown to have significant activity against Aurora kinases and multiple tyrosine-protein kinases, including tyrosine-protein kinase receptor FLT3, protooncogene c-Kit, vascular endothelial growth factor receptor VECFR-2, basic fibroblast growth factor FGFR-1 and FGFR-3, and tyrosine-protein kinase JAK2. ENMD-2076 has potent activity against various cultured tumor cells through multiple effects, including induction of early caspase-dependent apoptosis, modulation of the expression of anti-and proapoptotic proteins to favor cell death, inhibition of the phosphatidylinositol 3-kinase (PI3K)/protein kinase Akt pathway and Aurora kinase A and B, signaling through FGFR-3 and VEGFR, and induction of G 2/M cell cycle arrest. Potent antitumor activity in mice bearing cancer cell lines or human tumor xenografts, including human colorectal cancer, multiple myeloma, leukemia and breast cancer, is also observed. Phase I trials of ENMD-2076 are currently ongoing in solid tumors and hematologic malignancies, with preliminary results showing that the drug has acceptable toxicity and shows promising activity in at least ovarian and colon cancer, multiple myeloma and acute myeloid leukemia. Studies directed at better defining the spectrum of antitumor activity of ENMD-2076 and the relative importance of its apparently different mechanisms of action will allow the design of rational combinations of ENMD-2076 with other anticancer drugs in future clinical trials.",
author = "S. Zhang and Sherif Farag",
year = "2011",
doi = "10.1358/dof.2011.036.01.1561064",
language = "English (US)",
volume = "36",
pages = "5--15",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "1",

}

TY - JOUR

T1 - Aurora kinase A inhibitor protein kinase inhibitor oncolytic

AU - Zhang, S.

AU - Farag, Sherif

PY - 2011

Y1 - 2011

N2 - ENMD-2076 is a novel, orally active molecule that has been shown to have significant activity against Aurora kinases and multiple tyrosine-protein kinases, including tyrosine-protein kinase receptor FLT3, protooncogene c-Kit, vascular endothelial growth factor receptor VECFR-2, basic fibroblast growth factor FGFR-1 and FGFR-3, and tyrosine-protein kinase JAK2. ENMD-2076 has potent activity against various cultured tumor cells through multiple effects, including induction of early caspase-dependent apoptosis, modulation of the expression of anti-and proapoptotic proteins to favor cell death, inhibition of the phosphatidylinositol 3-kinase (PI3K)/protein kinase Akt pathway and Aurora kinase A and B, signaling through FGFR-3 and VEGFR, and induction of G 2/M cell cycle arrest. Potent antitumor activity in mice bearing cancer cell lines or human tumor xenografts, including human colorectal cancer, multiple myeloma, leukemia and breast cancer, is also observed. Phase I trials of ENMD-2076 are currently ongoing in solid tumors and hematologic malignancies, with preliminary results showing that the drug has acceptable toxicity and shows promising activity in at least ovarian and colon cancer, multiple myeloma and acute myeloid leukemia. Studies directed at better defining the spectrum of antitumor activity of ENMD-2076 and the relative importance of its apparently different mechanisms of action will allow the design of rational combinations of ENMD-2076 with other anticancer drugs in future clinical trials.

AB - ENMD-2076 is a novel, orally active molecule that has been shown to have significant activity against Aurora kinases and multiple tyrosine-protein kinases, including tyrosine-protein kinase receptor FLT3, protooncogene c-Kit, vascular endothelial growth factor receptor VECFR-2, basic fibroblast growth factor FGFR-1 and FGFR-3, and tyrosine-protein kinase JAK2. ENMD-2076 has potent activity against various cultured tumor cells through multiple effects, including induction of early caspase-dependent apoptosis, modulation of the expression of anti-and proapoptotic proteins to favor cell death, inhibition of the phosphatidylinositol 3-kinase (PI3K)/protein kinase Akt pathway and Aurora kinase A and B, signaling through FGFR-3 and VEGFR, and induction of G 2/M cell cycle arrest. Potent antitumor activity in mice bearing cancer cell lines or human tumor xenografts, including human colorectal cancer, multiple myeloma, leukemia and breast cancer, is also observed. Phase I trials of ENMD-2076 are currently ongoing in solid tumors and hematologic malignancies, with preliminary results showing that the drug has acceptable toxicity and shows promising activity in at least ovarian and colon cancer, multiple myeloma and acute myeloid leukemia. Studies directed at better defining the spectrum of antitumor activity of ENMD-2076 and the relative importance of its apparently different mechanisms of action will allow the design of rational combinations of ENMD-2076 with other anticancer drugs in future clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84952980729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952980729&partnerID=8YFLogxK

U2 - 10.1358/dof.2011.036.01.1561064

DO - 10.1358/dof.2011.036.01.1561064

M3 - Article

AN - SCOPUS:84952980729

VL - 36

SP - 5

EP - 15

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 1

ER -